Skip header and navigation
COVID-19 Rapid Evidence Reviews
  Refine Search

11 records – page 1 of 2.

How effective is surveillance antigenic testing?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc256
Document Type
Evidence Search Report
Review Code
EOC012601-01 ESR
Question Submitted
January 26, 2021
Date Completed
January 29, 2021
Status
3. Completed
Research Team
EOC
Complete Date: January 29, 2021 Subject(s): Antigens, Asymptomatic, Screening Methods Cite
More detail
Document Type
Evidence Search Report
Review Code
EOC012601-01 ESR
Question Submitted
January 26, 2021
Date Completed
January 29, 2021
Status
3. Completed
Research Team
EOC
Category
Diagnostics
Infection Prevention and Control
Subject
Screening
Antigens
Asymptomatic
Testing
Priority Level
Level 3 Two weeks (14 days)
Cite As
Dalidowicz, M; Young, C. How effective is surveillance antigenic testing? 2021 Jan 29; Document no.: EOC012601-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 32 p. (CEST evidence search report).
Related Documents
Documents
thumbnail

EOC012601-01 ESR

Read PDF Download PDF
Less detail

How effective is surveillance antigenic testing?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc263
Document Type
Rapid Review
Review Code
EOC012601 RR
Question Submitted
January 26, 2021
Date Completed
February 12, 2021
Status
3. Completed
Research Team
EOC
that this test is appropriate for contagious case identification and asymptomatic case screening, especially
More detail
Document Type
Rapid Review
Review Code
EOC012601 RR
Question Submitted
January 26, 2021
Date Completed
February 12, 2021
Status
3. Completed
Research Team
EOC
Key Findings
· Studies suggest that antigen-based rapid diagnostic tests (Ag-RDTs) can be used in a population level with high prevalence of COVID-19 disease where health systems are overwhelmed or where nucleic acid amplification tests (NAATs) such as real time reverse transcription polymerase chain reaction (rRT-PCR) are not available. · The Canadian COVID-19 Testing and Screening Expert Advisory Panel recommends the use of frequent screening with rapid diagnostic tests in selected groups to limit outbreaks. · WHO and European Center for Disease Prevention and Control recommend using Ag-RDTs with high sensitivity and specificity when NAATs are not available or turnaround time negatively affects NAATs’ clinical utility. For example, COVID-19 Ag-RDTs can be used to surveil health care workers or residents of congregate dwellings during outbreaks or when community transmission rates are high, to screen at-risk individuals to support outbreak investigations, or to screen suspected COVID-19 outbreaks in early stages in settings where NAATs are not available. · WHO does not recommend Ag-RDTs usage when expected prevalence is low (e.g., screening at points of entry) unless an Ag-RDT’s specificity is high (>99%). · Studies have shown that Panbio™ COVID-19 Ag Test (Abbott) can have overall sensitivity of 72.6% to 95.2% and specificity of 98.0% to 100% and suggest that this test is appropriate for contagious case identification and asymptomatic case screening, especially in high prevalence (>5%) settings. · WHO recommends that iterative Ag-RDT testing or confirmatory rRT-PCR testing be done in symptomatic patients or asymptomatic contacts of COVID-19 cases since a negative Ag-RDT result cannot completely exclude an active COVID-19 infection. · Challenges of population level testing (whether they succeed or fail) such as required logistics and resources (e.g., immunizers, access to Ag-RDTs and equipment), performance accuracy of Ag-RDTs (e.g., false positive or negative rates in real world settings), and public trust and engagement in testing and future measures (e.g., vaccine uptake) are yet to be considered.
Category
Diagnostics
Infection Prevention and Control
Subject
Antigens
Asymptomatic
Screening
Priority Level
Level 3 Two weeks (14 days)
Cite As
Azizian, A; Groot, G; Reeder, B; Hamula, C; Dalidowicz, M; Young, C. How effective is surveillance antigenic testing? 2021 Feb 12; Document no.: EOC012601 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 32 p. (CEST rapid review report)
Related Documents
Documents
thumbnail

EOC012601 RR

Read PDF Download PDF
Less detail

What is the evidence around testing for asymptomatic COVID on the day of surgery?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc486
Document Type
Evidence Search Report
Review Code
EOC220505 ESR
Question Submitted
May 18, 2022
Date Completed
May 25, 2022
Status
3. Completed
Research Team
EOC
Team EVIDENCE SEARCH REPORT Review Question: What is the evidence around testing for asymptomatic
More detail
Document Type
Evidence Search Report
Review Code
EOC220505 ESR
Question Submitted
May 18, 2022
Date Completed
May 25, 2022
Status
3. Completed
Research Team
EOC
Category
Diagnostics
Healthcare Services
Subject
Asymptomatic
Infection Prevention and Control
Surgical Procedures
Testing
Population
All
Priority Level
Level 1 2-3 days
Cite As
Dalidowicz, M; Mueller, M. What is the evidence around testing for asymptomatic COVID on the day of surgery? 2022 May 25, Document no.: EOC220505 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 32 p. (CEST rapid review report).
Related Documents
Documents
thumbnail

EOC220505 ESR

Read PDF Download PDF
Less detail

What is the evidence around testing for asymptomatic COVID on the day of surgery?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc495
Document Type
Table
Review Code
EOC220505 RR Table
Question Submitted
May 18, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
EOC
: What is the evidence around testing for asymptomatic COVID on the day of surgery? Review Code
More detail
Document Type
Table
Review Code
EOC220505 RR Table
Question Submitted
May 18, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
EOC
Category
Diagnostics
Healthcare Services
Subject
Asymptomatic
Infection Prevention and Control
Surgical Procedures
Testing
Population
All
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. What is the evidence around testing for asymptomatic COVID on the day of surgery? 2022 Jun 06, Document no.: EOC220505 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

EOC220505 RR Table

Download File
Less detail

What is the evidence around testing for asymptomatic COVID on the day of surgery?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc497
Document Type
Rapid Review
Review Code
EOC220505 RR
Question Submitted
May 18, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
EOC
Team RAPID REVIEW REPORT What is the evidence around testing for asymptomatic COVID on the day
More detail
Document Type
Rapid Review
Review Code
EOC220505 RR
Question Submitted
May 18, 2022
Date Completed
June 6, 2022
Status
3. Completed
Research Team
EOC
Key Findings
Current requirements for preoperative COVID-19 testing are highly variable across jurisdictions, with some requiring preoperative testing for all patients 24-72 hours prior to surgery and some not recommending testing of asymptomatic patients at all
Studies describing low rates of asymptomatic positivity are limited to early in the pandemic, prior to the widespread availability of vaccines and the emergence of variant strains. These studies show very low rates of asymptomatic positives when testing within 72 hours of surgery
Mixed evidence on safety of surgery in asymptomatic COVID-19 infected patients
Preliminary evidence indicates that it may be safe to discontinue asymptomatic preoperative testing, but there are too many unknowns that have not yet been addressed with regards to the impact of vaccination status and the altered pathophysiology associated with currently circulating variants
Category
Diagnostics
Healthcare Services
Subject
Asymptomatic
Infection Prevention and Control
Surgical Procedures
Testing
Population
All
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. What is the evidence around testing for asymptomatic COVID on the day of surgery? 2022 Jun 06, Document no.: EOC220505 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report).
Related Documents
Documents
thumbnail

EOC220505 RR

Read PDF Download PDF
Less detail

What is the period of communicability of symptomatic SARS-CoV-2?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc56
Document Type
Evidence Search Report
Review Code
INF042401-01 ESR
Question Submitted
24-Apr-2020
Date Completed
25-Apr-2020
Status
3. Completed
Research Team
Infectious Disease
of available evidence on COVID-19 transmission from symptomatic, pre-symptomatic and asymptomatic people
More detail
Document Type
Evidence Search Report
Review Code
INF042401-01 ESR
Question Submitted
24-Apr-2020
Date Completed
25-Apr-2020
Status
3. Completed
Research Team
Infectious Disease
Category
Infection Prevention and Control
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Natural History
Asymptomatic
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS-CoV-2? 2020 Apr 25; Document no.: INF042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report)
Related Documents
Documents
thumbnail

INF042401-01 ESR

Read PDF Download PDF
Less detail

What is the period of communicability of symptomatic SARS-CoV-2?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc57
Document Type
Rapid Review
Review Code
INF042401 RR
Question Submitted
24-Apr-2020
Date Completed
April 27, 2020
Status
3. Completed
Research Team
Infectious Disease
suggest that persons may be asymptomatic carriers although it needs to be confirmed whether
More detail
Document Type
Rapid Review
Review Code
INF042401 RR
Question Submitted
24-Apr-2020
Date Completed
April 27, 2020
Status
3. Completed
Research Team
Infectious Disease
Key Findings
The period of communicability of symptomatic SARS CoV-2 infections remains unclear.
Viral RNA shedding measured from the onset of illness is a common proxy used to estimate the period of communicability; however, confirmation of the viability of viral remnants in secretions through culture or other methods seldom occurs in practice.
Several factors including age, male sex and clinical severity influence individual variation in viral shedding and suggest the need for tailored control efforts.
Temporal patterns in viral shedding across different types of bodily secretions has implications for transmissibility and criteria for discontinuation of control measures during convalescence.
Category
Infection Prevention and Control
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Natural History
Asymptomatic
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Williams-Roberts, H; Lee, S; Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS CoV-2? 2020 Apr 27; Document no.: INF042401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST rapid review report)
Related Documents
Documents
thumbnail

INF042401 RR

Read PDF Download PDF
Less detail

What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update]

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc75
Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Review Title: What proportion of disease transmission is due to asymptomatic, pre- symptomatic
More detail
Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
COVID-19 is primarily transmitted by symptomatic patientsand presymptomatic individuals.·Moderate grade evidence estimates that approximately 20% of COVID-19 transmission may bedue to that from presymptomatic individuals.However, estimates range from 6.4% -47%.·Asymptomatic individuals and environmental contaminationappear to contributelessto disease transmission,with estimated proportionsof 6% and 10%, respectivelyfrom modelling studies
Category
Clinical Presentation
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Asymptomatic
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B; What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? 2020 May 8; Document no.: LAB040701v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST rapid review report)
Similar Reviews
EPM051301 RR
Review History
LAB040701 RR: April 7, 2020
Related Documents
Documents
thumbnail

LAB040701v2 RR

Read PDF Download PDF
Less detail

What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update]

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc78
Document Type
Evidence Search Report
Review Code
LAB040701v2-01 ESR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
QUESTION: What Proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic
More detail
Document Type
Evidence Search Report
Review Code
LAB040701v2-01 ESR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Category
Clinical Presentation
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Asymptomatic
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? 2020 May 8; Document no.: LAB040701v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 25 p. (CEST evidence search report)
Review History
LAB040701 RR: April 7, 2020
Related Documents
Documents
thumbnail

LAB040701v2-01 ESR

Read PDF Download PDF
Less detail

What proportion of disease transmission is due to persons who are asymptomatic over the entire course of illness?

https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc88
Document Type
Evidence Search Report
Review Code
EPM051301-01 ESR
Question Submitted
May 13, 2020
Date Completed
May 13, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
QUESTION: What proportion of disease transmission is due to persons who are asymptomatic over the entire
More detail
Document Type
Evidence Search Report
Review Code
EPM051301-01 ESR
Question Submitted
May 13, 2020
Date Completed
May 13, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Category
Clinical Presentation
Epidemiology
Subject
Symptoms
Asymptomatic
Transmission
Natural History
Priority Level
Level 4 completed within 1 week
Cite As
Dalidowicz, M; Young, C; Mueller, M. What proportion of disease transmission is due to persons who are asymptomatic over the entire course of illness? 2020 May 13; Document no.: EPM051301-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report)
Related Documents
Documents
thumbnail

EPM051301-01 ESR

Read PDF Download PDF
Less detail

11 records – page 1 of 2.